Watch KBLB. Know when insiders buy.
One email the day a filing lands. Free.
KBLB
Kraig Biocraft Laboratories, Inc.
0.08
+0.00 +0.00%
USD · close Sep 18
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
7
FLAG · shorts 7
Insiders, 90 days
0
no open-market filings in 90 days
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $88MP/E —DIV YIELD —FCF YIELD -2.37%REV TTM —NET INCOME −$4.1MNET CASH $3.4M52W 0.08 – 0.16SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$703K | −$910K | — | 0.00 | −$599K | $29K | −$627K | Aug 13 |
| Q1 2026 · Mar 31 | — | — | — | −$826K | −$943K | — | 0.00 | −$530K | $14K | −$544K | May 14 |
| Q4 2025 · Dec 31derived | — | — | — | −$723K | −$788K | — | 0.00 | −$449K | $2K | −$451K | Mar 30 |
| Q3 2025 · Sep 30 | — | — | — | −$1.4M | −$1.5M | — | 0.00 | −$462K | $0 | −$462K | Nov 12 |
| Q2 2025 · Jun 30 | — | — | — | −$638K | −$726K | — | 0.00 | −$443K | — | — | Aug 13 |
| Q1 2025 · Mar 31 | — | — | — | −$580K | −$600K | — | 0.00 | −$434K | — | — | May 14 |
| Q4 2024 · Dec 31derived | — | — | — | −$716K | −$852K | — | 0.00 | −$513K | — | — | Mar 30 |
| Q3 2024 · Sep 30 | — | — | — | −$424K | −$433K | — | 0.00 | −$326K | — | — | Nov 12 |
| Q2 2024 · Jun 30 | — | — | — | −$1.5M | −$1.6M | — | 0.00 | −$511K | — | — | Aug 14 |
| Q1 2024 · Mar 31 | — | — | — | −$449K | −$508K | — | 0.00 | −$490K | — | — | May 15 |
| Q4 2023 · Dec 31derived | — | — | — | −$1.2M | −$1.3M | — | 0.00 | −$328K | $0 | −$328K | Mar 28 |
| Q3 2023 · Sep 30 | — | — | — | −$459K | −$549K | — | 0.00 | −$249K | — | — | Nov 13 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$3.4M | −$3.6M | — | 0.00 | −$1.8M | $5K | −$1.8M | — | — |
| FY2024 · to Dec 31 | — | — | −$3.1M | −$3.4M | — | 0.00 | −$1.8M | $4K | −$1.8M | — | — |
| FY2023 · to Dec 31 | — | — | −$2.6M | −$3M | — | 0.00 | −$1.2M | $6K | −$1.3M | — | — |
| FY2022 · to Dec 31 | — | — | −$2.1M | −$3.8M | — | 0.00 | −$1.9M | $5K | −$1.9M | — | — |
| FY2021 · to Dec 31 | — | — | −$2.8M | −$8M | — | -0.01 | −$1.8M | $97K | −$1.9M | — | — |
| FY2020 · to Dec 31 | — | — | −$4.5M | −$5M | — | -0.01 | −$1.3M | — | — | — | — |
Every number comes from Kraig Biocraft Laboratories, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.